Circulation Research
JOURNAL OF THE AMERICAN HEART ASSOCIATION

cAMP-Binding Protein Epac Induces Cardiomyocyte Hypertrophy

Eric Morel, Andrea Marcantoni, Monique Gastineau, Rikke Birkedal, Francesca Rochais, Anne Garnier, Anne-Marie Lompré, Grégoire Vandecasteele and Frank Lezoualch

Circ. Res. published online Nov 3, 2005;
DOI: 10.1161/01.RES.0000194325.31359.86
Circulation Research is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
Copyright © 2005 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org

Subscriptions: Information about subscribing to Circulation Research is online at
http://circres.ahajournals.org/subsriptions/

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email:
journalpermissions@lww.com

Reprints: Information about reprints can be found online at
http://www.lww.com/static/html/reprints.html

Downloaded from circres.ahajournals.org at Biblioteche biomediche Universita' di Torino on November 4, 2005

cAMP-Binding Protein Epac Induces Cardiomyocyte Hypertrophy

Eric Morel, Andrea Marcantoni, Monique Gastineau, Rikke Birkedal, Francesca Rochais, Anne Garnier, Anne-Marie Lompré, Grégoire Vandecasteele, Frank Lezoualc'h

Abstract—cAMP is one of the most important second messenger in the heart. The discovery of Epac as a guanine exchange factor (GEF), which is directly activated by cAMP, raises the question of the role of this protein in cardiac cells. Here we show that Epac activation leads to morphological changes and induces expression of cardiac hypertrophic markers. This process is associated with a Ca^{2+}-dependent activation of the small GTPase, Rac. In addition, we found that Epac activates a prohypertrophic signaling pathway, which involves the Ca^{2+} sensitive phosphatase, calcineurin, and its primary downstream effector, NFAT. Rac is involved in Epac-induced NFAT dependent cardiomyocyte hypertrophy. Blockade of either calcineurin or Rac activity blunts the hypertrophic response elicited by Epac indicating these signaling molecules coordinately regulate cardiac gene expression and cellular growth. Our results thus open new insights into the signaling pathways by which cAMP may mediate its biological effects and identify Epac as a new positive regulator of cardiac growth. **(*Circ Res*. 2005;97:0-0.)**

American Heart Association.

Key Words: cAMP ■ guanine nucleotide exchange factor ■ small G protein ■ transcription factor

Circulation Research FIRST PROOF ONLY

In the heart, cyclic adenosine 3′,5′-monophosphate (cAMP) regulates many physiological processes such as contractility and relaxation. Classically, these effects are attributed to activation of hyperpolarization-activated cyclic nucleotide-gated channels and protein kinase A (PKA) by cAMP.[1] The recent discovery of Epac as proteins which are directly activated by cAMP has broken the dogma surrounding cAMP and PKA.[2–4] Epac proteins are guanine nucleotide exchange factors (GEFs) that bind cAMP with affinities similar to that of the regulatory subunit of PKA.[2,3] They have been shown to function as GEFs for the Ras-like small GTPases Rap1 and Rap2 and are directly activated by cAMP in a PKA independent manner.[4] There are two isoforms of Epac, Epac 1 and Epac 2 both consisting of a regulatory and a catalytic region.[2,3] Epac 2 has an additional cAMP binding domain that is dispensable for cAMP-induced Rap activation.[5] After cAMP binding, Epac catalyzes the exchange of GDP for GTP on the small GTPases Rap, allowing interaction with their target effectors.[6] Recent studies indicate that Epac is involved in cell adhesion,[7,8] neurite extension,[9] and regulates insulin secretion and the amyloid precursor protein processing.[10,11] To date the role of Epac in the heart is unknown.

Among the superfamily of small G proteins, the Rho family, which includes Rho, Rac, and Cdc42, has attracted much interest for they have been shown to play key roles in the generation of cytoskeletal structures.[12] Indeed, Rho is important for the formation of stress fibers and focal adhesions in fibroblasts, whereas Rac and Cdc42 are involved in the regulation of more dynamic structures such as membrane ruffles, lamellipodia and filopodia.[12] Several studies have pointed out the role of Rho proteins in the development of cardiomyocyte hypertrophy.[13] For instance, two potent hypertrophic stimuli, endothelin 1 (ET-1) and phenylephrine (PE), induce rapid activation of endogenous Rac in neonatal cardiomyocytes.[14] In addition, adenoviral infection of cardiomyocytes with a constitutive active form of Rac (Rac^{G12V}) increases protein synthesis and promotes morphological changes associated with myocyte hypertrophy.[15] In vivo evidence for the role of Rho proteins in cardiac hypertrophy came from transgenic mice specifically expressing Rac^{G12V} in the heart. These mice develop a dilated cardiomyopathy associated with deregulation of cardiomyocyte focal adhesions.[16] These data suggest that Rho proteins, especially Rac control hypertrophic response and are likely to be involved in cardiac remodeling, and the pathogenesis of cardiomyopathy characterized by cellular enlargement.

Recently, we have provided experimental evidence that Epac stimulates the activity of the small GTPase, Rac, in a cAMP-dependent but PKA-independent manner in neuronal cells.[11] These observations combined with the high expression of Epac in the heart[2,3] prompted us to focus our research on the potential role of Epac in cardiomyocyte hypertrophy.

Original received May 27, 2005; revision received October 12, 2005; accepted October 25, 2005.

From the Cardiologie Cellulaire et Moléculaire, Inserm U-446, IFR-75, Faculté de Pharmacie, Université Paris XI, 5 Rue JB Clément, 92296 Chātenay Malabry, France

Present address for A.-M.L.: Inserm U-621, Faculté de Médecine Pitié-Salpêtrière, 91, bd de l'Hôpital, 75634 Paris Cedex 13, France.

Correspondence to Frank Lezoualc'hor, Cardiologie Cellulaire et Moléculaire, Inserm U-446, IFR-75, Faculté de Pharmacie, Université Paris XI, 5 Rue JB Clément, 92296 Chātenay Malabry, France. E-mail Frank.Lezoualch@cep.u-psud.fr

© 2005 American Heart Association, Inc.

Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/01.RES.0000194325.31359.86



Figure 1. Epac activates the small G protein Rac in primary ventricular cardiomyocytes. Cardiomyocytes were infected with either Ad.GFP as a control or with Ad.Epac^{WT} or Ad.Epac-ΔcAMP as described in Materials and Methods. Two days after infection, cells were treated or not for 10 minutes with the selective activator of Epac, 8-CPT (10^{-6} mol/L). Amounts of Rac-GTP were determined by pull-down experiments. A control for total Rac expression (total lysates) is shown. The upper panel shows a typical immunoblot. Expression of recombinant proteins was determined by Western blot using an anti-HA antibody. The lower panel shows means±SEM of 3 independent experiments. Results are expressed as fold activation of control cells. *$P<0.05$, **$P<0.01$ compared with control.

Circulation Research FIRST PROOF ONLY

Here we found that Epac stimulates the activity of the small GTPase, Rac, and increases the expression of hypertrophic gene markers in primary cardiac myocytes. Furthermore, we show that Epac induces cardiomyocyte hypertrophy. This process is associated with the activation of Rac and the calcineurin/NFAT signaling pathway, which coordinately regulates cell growth and gene expression. Altogether, these findings identify the cAMP-binding protein, Epac, as a new positive regulator of cardiac growth.

Materials and Methods

Adenoviral Infection

Bicistronic adenoviruses (Ad5) bearing either Epac^{WT} or EpacΔcAMP under the control of a cytomegalovirus promoter and green fluorescent protein (GFP) under internal ribosomal entry site control were constructed and amplified at the Genethon Center of Evry (France). Adenoviruses encoding VIVIT, a selective peptide inhibitor of calcineurin-mediated NFAT activation, and Rac were provided by Drs S. Kraner and C. Norris (University of Kentucky) and T. Finkel (Cardiology Branch, National Heart, NIH, Bethesda, Md), respectively. One day after plating, cardiomyocytes were incubated for 2 hours with recombinant adenoviruses. After removal of the virus suspension, cells were replaced in maintenance medium for 2 days and then stimulated with the different drugs. Viruses were used at a multiplicity of infection (MOI) of 100.

Plasmid Constructs and Transfection

The plasmid constructs were generously provided by the following: the rat ANF promoter fused to the luciferase reporter gene (ANF-Luc) by Dr K. Knowlton, Luciferase reporter genes linked to promoters for skeletal muscle α-actin (SkM-α-actin-Luc) and serum response element-regulated c-*fos* (c-*fos*-SRE-Luc) by Dr M. D. Schneider, Epac1 plasmid constructs by Drs J. Bos and X. Cheng. The luciferase reporter plasmid driven by four NFAT consensus binding sites (NFAT-Luc) was obtained from Stratagene. Transient transfection experiments were performed with Lipofectamine 2000 (Invitrogen Life Technologies, France) in optimum medium in the presence of 1 μg of the various plasmid constructs according to the manufacturers' instructions.

Rac Activation Assay

Rac pull-down experiments were performed using a GST fusion protein containing the Cdc42/Rac Interactive Binding Domain (CRIB) of p21-activated kinase (PAK) exactly as previously described.[11]

Statistical Analysis

Results are expressed as means±SEM. Differences between groups have been analyzed by one-way ANOVA followed by unpaired Student *t* test. Differences were considered significant at $P<0.05$, $P<0.01$, and $P<0.001$.

For a description of other methods, see the expanded Materials and Methods, available online at http://circres.ahajournals.org.

Results

Epac Activates the Small G Protein Rac in Cardiomyocytes

Activation of endogenous Epac with a selective activator of this GEF, 8-pCPT-2′-O-Me-cAMP (8-CPT), which does not activate PKA[17] increased Rac activation in rat cardiac myocytes (Figure 1). Similarly, infection of cardiomyocytes with an adenovirus encoding Epac1^{WT} (Ad.Epac^{WT}) significantly enhanced Rac GTP-loading compared with control cells infected with GFP (Figure 1). Rac activation was further increased when cells infected with Ad.Epac^{WT} were treated with 8-CPT (Figure 1). An adenovirus bearing a constitutive activated form of Epac1 (Ad.Epac-ΔcAMP)[2] also induced Rac activation (Figure 1). Altogether, these results demonstrate that recombinant and native Epac increase the amount of Rac-GTP in cardiomyocytes.



Figure 2. Epac stimulates a hypertrophic pattern of gene expression. A, C, and D, Neonatal cardiomycocytes were transfected with ANF-Luc, SkM-α-actin-Luc or c-*fos*-SRE-Luc and Epac^{WT}, Epac-ΔcAMP, Rac^{G12V}, or the empty vector (mock) as control and treated or not with 8-CPT (10^{-6} mol/L). Two days after transfection, cells were assayed for Luc activity. Results are expressed as percentage activation of control. Results are means±SEM from 3 independent experiments performed in triplicates. B, Epac induces expression of ANF mRNA. Cardiomyocytes were infected with Ad.Epac^{WT}, Ad.Rac^{G12V}, or Ad.GFF (control) and stimulated or not with 8-CPT (10^{-6} mol/L) for 2 days. ANF mRNA expression was determined by quantitative PCR. Values are expressed relative to the ANF/GCB ratio and results were normalized to control for each experiment. Results are presented as the mean±SEM of 3 independent experiments performed in duplicates. *$P<0.05$, **$P<0.01$, ***$P<0.001$ compared with control.

Epac Increases the Expression of Hypertrophy Gene Markers

As Rac has been found to be involved in cardiac myocyte hypertrophy,[15,16] we next tested the potential involvement of Epac in this process. Re-expression of embryonic genes and transient activation of immediate early genes are frequently used indexes of myocyte hypertrophy.[18] The ability of Epac to stimulate gene expression was determined using luciferase (Luc) constructs under the control of promoters for ANF, SkM α-actin, and the c-*fos*-SRE. Figure 2A shows a three-fold activation of the ANF-Luc reporter gene in neonatal cardiomyocytes stimulated with 8-CPT compared with control cells. Transient transfection of Epac^{WT} or Epac-ΔcAMP increased the basal level of ANF-Luc activity (Figure 2A). The effect of Epac^{WT} on ANF-Luc activity was further increased by the application of 8-CPT (Figure 2A). Rac^{G12V} mimicked the effect of Epac on ANF-Luc activity (Figure 2A). Next, to analyze the effect of Epac on ANF mRNA content in cardiac myocytes, we used Ad.EpacWT to maximize the expression of this GEF in primary cardiomyocyte. Consistent with the effect of Epac on ANF-Luc reporter gene, endogenous expression of ANF mRNA was significantly increased in cardiomyocytes infected with Ad.Epac^{WT} and stimulated or not with 8-CPT, as compared with control cells (Figure 2B). Similar results were obtained with an adenovirus expressing Rac^{G12V} (Ad.Rac^{G12V}) (Figure 2B). In addition, when cotransfection experiments were performed with SkM-α-actin-Luc or c-*fos*-SRE-Luc, 8-CPT, Epac^{WT}, Epac-ΔcAMP, or Rac^{G12V} significantly increased Luc activity compared with control cells (Figure 2C and 2D). The effect of Epac^{WT} on Luc activity was further increased by the application of 8-CPT (Figure 2C and 2D).

Epac Increases Cardiomyocyte Size and Sarcomeric Organization

Further studies were undertaken to determine the effects of Epac on other features of the hypertrophic program such as cell size and sarcomeric organization. Cardiomyocyte treatment with Ad.GFP and 8-CPT as well as infection of cardiomyocytes with Ad.Epac^{WT} induced an apparent increase of the F-actin meshwork and a heavily striated appearance, reflecting the organization of this F-actin cytoskeleton into sarcomeric structures, as compared with cardiomyocytes infected with Ad.GFP alone (Figure 3A). Cells overexpressing Epac were hypertrophied and were not contaminated by fibroblast as shown by the α-actinin staining in supplementary Figure I. In addition, the effects of Epac on sarcomeric organization were comparable to Ad.Epac-ΔcAMP (data not shown) and PE (Figure 3A), a well-known inducer of cardiac hypertrophy.

Next, we measured the effect of Epac on cell surface area. Activation of endogenous Epac with 8-CPT produced a two-fold increase in cell surface area when compared with cells infected with control Ad.GFP (Figure 3B). Identical results were obtained when cardiomyocytes were infected with Ad.Epac^{WT} (Figure 3B), Ad.Epac-ΔcAMP (data not shown), or Ad.GFP and treated with PE (Figure 3B). The effect of Ad.Epac^{WT} on cell surface area was not further increased in the presence of 8-CPT suggesting that basal intracellular cAMP was sufficient to activate recombinant Epac to induce its maximal effect on protein synthesis (Figure 3B). Finally, the effect of Epac on protein synthesis was analyzed by measurement of [^{3}H]-leucine incorporation into cardiac myocytes. Expression of this cAMP-GEF resulted in an increase in [^{3}H]-leucine uptake into cardiomyocytes (Figure 3C). Similarly, cell treatment with 8-CPT or the gold standard, PE resulted in an approximately two-fold increase in protein synthesis (Figure 3C). Altogether, these results show that Epac activation confers to primary cardiomyocytes all the features of the hypertrophic phenotype.

Intracellular Ca^{2+} Is Involved in Epac-Dependent Rac Activation

Alterations in intracellular Ca^{2+} handling progressively exacerbate a hypertrophic or cardiomyopathic phenotype, in part

Circulation Research
FIRST PROOF ONLY





Figure 3. Epac induces cardiomyocytes hypertrophy. A, Fluorescent microscopic analyses of the effects of Epac on sarcomeric organization. Morphology of representative myocytes 48 hours after infection with Ad.GFP as a control, or Ad.Epac^{WT} is shown. The Epac selective activator, 8-CPT was used at 10^{-6} mol/L for 2 days in cells infected with Ad.GFP. Positive control cells were infected with Ad.GFP and treated with PE (10^{-5} mol/L) for 2 days. Actin filaments were visualized by using Rhodamin-conjugated phalloidin. B, Photographic images of cells treated as above were digitized. The areas (10^{-6} m^2) of 30 to 50 individualized cells per condition from 2 to 3 independent experiments were determined by computer-assisted planimetry. Values show the means±SEM. C, [^{3}H]-leucine incorporation. Cardiomyocytes were treated as in (A) and total radioactivity of incorporated [^{3}H]-leucine into proteins was determined by scintillation counting. The figure shows the mean±SEM of data for 3 experiments performed in duplicate. *$P<0.05$, **$P<0.01$, ***$P<0.001$ compared with control Ad.GFP.

through sustained activation of Ca^{2+}-sensitive signal transduction pathways.[19] Given the involvement of Epac in cardiac hypertrophy, we examined whether its activation could affect intracellular Ca^{2+} concentration ($[Ca^{2+}]_i$) in neonatal myocytes (Figure 4). At physiological external $[Ca^{2+}]$, cardiac myocytes exhibited spontaneous Ca^{2+} transients with a low frequency (0.120±0.015 Hz, n=20) (Figure 4A). Application of the Epac agonist 8-CPT triggered a dramatic increase in the frequency of these Ca^{2+} oscillations (0.51±0.04 Hz, n=7) without changing the amplitude of the spikes. This effect was also observed at 100 nM 8-CPT (0.40±0.05 Hz, n=13, data not shown).

Because Epac induced Rac activation, we examined the dependence of Rac activation on Ca^{2+} signaling. Treatment of cardiac myocytes with the Ca^{2+} ionophore ionomycin as well as an inhibitor of the Ca^{2+}-ATPase, thapsigargin increased Rac activation in a time dependent manner (Figure 4B and 4C). The effect of ionomycin and thapsigargin on Rac activation was as potent as the positive control, PE (Figure 4B and 4C). Pretreatment with BAPTA-AM, an intracellular Ca^{2+} chelator, attenuated Epac-induced Rac activation (Figure 4D). From these results we conclude that elevation of intracellular $[Ca^{2+}]_i$ after Epac activation is sufficient to activate Rac.



Figure 4. Intracellular Ca^{2+} is involved in Epac- dependent Rac activation. A, Effect of 8-CPT (10^{-5} mol/L) on spontaneous spiking activity at 1.8×10^{-3} mol/L external [Ca^{2+}]. Cardiomyocytes at day 1 or 2 after plating were loaded with the Ca^{2+} indicator Fluo3-AM and perfused with a control external Ringer solution. B to D, Effect of ionomycin, thapsigargin and BAPTA-AM on Rac activation. Ventricular cardiomyocytes were treated at 2 days in vitro with either ionomycin (10^{-6} mol/L) (B) or thapsigargin (0.2×10^{-6} mol/L) (C) for different times of incubation or PE (10^{-5} mol/L) for 15 minutes. D, Cells were pretreated with BAPTA-AM (1.5×10^{-5} mol/L) for 10 minutes and then they were stimulated with 8-CPT (10^{-5} mol/L) for 15 minutes. The amount of Rac-GTP was determined by pull-down experiments.

Circulation Research
AMERICAN HEART ASSOCIATION
FIRST PROOF ONLY

Epac Activates the Hypertrophic Calcineurin/NFAT Signaling Pathways

One prominent Ca^{2+}-dependent pathway that plays a crucial role in cardiomyocyte hypertrophy involves the phosphatase calcineurin.[20] Activation of calcineurin by Ca^{2+} results in the dephosphorylation and nuclear translocation of cytoplasmic NFAT transcription factors, which then upregulate transcription of hypertrophic genes. To test whether endogenous Epac may activate the hypertrophic calcineurin NFAT signaling pathway, cardiomyocytes were transfected with NFAT-Luc and treated or not with 8-CPT (Figure 5A). 8-CPT significantly increased NFAT transcriptional activity as compared with control cells (Figure 5A). Accordingly, 8-CPT increased NFAT nuclear translocation (supplementary Figure II). The stimulating effect of 8-CPT on NFAT-Luc was significantly blocked by a pharmacological inhibitor of calcineurin, cyclosporine A (CsA) or transfection of a dominant negative form of Epac (EpacΔ1 to 148)[21] (Figure 5A).

Recombinant Epac^{WT} also increased NFAT transcriptional activity which was blocked by CsA or an adenovirus bearing a selective peptide inhibitor of calcineurin named VIVIT (Ad.VIVIT)[22] (Figure 5B and 5C). Consistent with these findings, cardiac myocytes infected with Ad.Epac^{WT} and treated or not with 8-CPT (Figure 5D), or Ad.Epac-ΔcAMP (data not shown) had an increased content of mRNA encoding the modulatory calcineurin-interacting protein 1 (MCIP1), a mediator of calcineurin signaling during cardiac hypertrophy.[23] Furthermore, coinfection with Ad.VIVIT and Ad.Epac^{WT} reduced the enhancement of sarcomeric organization and cell surface area induced by Ad.Epac^{WT} (Figure 6A and 6B). Altogether these data show that NFAT is a downstream component of Epac hypertrophic signaling pathway.

Involvement of Rac in Epac-Induced NFAT-Dependent Cardiomyocyte Hypertrophy

Because Rac was found to be a downstream component of Epac signaling pathway (Figure 1), we next examined the involvement of Rac in Epac-induced NFAT transcriptional activity. Ad.Rac^{S17N} completely inhibited Epac-induced NFAT transcriptional activity (Figure 7A) whereas the stimulating effect of Rac^{G12V} on NFAT-Luc was blocked by CsA (Figure 7B). These data clearly indicate that Rac is able to influence the calcineurin/NFAT signaling pathway. The involvement of Rac in Epac signaling pathway controlling cardiomyocyte hypertrophy was further supported by the observation that Rac^{S17N} inhibited the stimulating effect of endogenous Epac activation or Epac^{WT} on ANF expression (Figure 7C and supplementary Figure III). Consistent with these findings, Ad.Rac^{S17N} inhibited Epac-induced cytoskeletal reorganization (Figure 7D) and increase in cell surface area (Figure 7E). Finally, as Rac has been shown to induce the production of reactive oxygen species (ROS),[24] we analyzed the effect of Epac^{WT} on ANF-Luc in the presence of the antioxidant, N-acetylcysteine (NAC). We found that NAC inhibited Epac-induced ANF-Luc activity suggesting that oxidative stress is increased by Epac (supplementary Figure IV).



Figure 5. Activation of NFAT by Epac. A to C, Effect of Epac on NFAT transcriptional activity. A, Cardiomycoytes were transfected with NFAT-Luc, Epac-Δ1 to 148, or the empty vector (mock) as control and treated or not with 8-CPT (10^{-6} mol/L) or CsA (0.5×10^{-6} mol/L). B and C, Cardiomyocytes infected with Ad.GFP (control), Ad.$Epac^{WT}$, or Ad.VIVIT were transfected with NFAT-Luc and treated as described. Two days after transfection, Luc activity was assayed. D, Epac increases MCIP1 expression. Cardiac myocytes infected with Ad.GFP (control) or Ad.$Epac^{WT}$ were treated or not with 8-CPT (10^{-6} mol/L) for 2 days. The ratio of MCIP1/GCB mRNA was determined by quantitative PCR. Values are expressed relative to the MCIP1/GCB ratio. Results were normalized to control for each experiment, and were expressed as means±SEM of at least 3 independent experiments performed in triplicate (A to C) or duplicate (D).

Discussion

The present study shows for the first time that cAMP-dependent activation of Epac induces cardiomyocyte hypertrophy. This is based on our observation that Epac activation leads to morphological changes, cytoskeletal reorganization, increases in protein synthesis, and induces expression of cardiac hypertrophic markers. In addition, we found that Epac activates a prohypertrophic signaling pathway which involves calcineurin and its primary downstream effector, NFAT. Epac-induced NFAT activation was dependent on Rac activity. Interestingly, overexpression of Epac was able to influence cardiomyocyte morphology without cAMP analogue treatment indicating that the level of intracellular cAMP was sufficient to activate the recombinant $Epac^{WT}$ protein. Similar observations have been reported in other cellular systems because transfection of $Epac^{WT}$ in HEK293 and COS cells has been previously shown to influence cell signaling and morphology at resting basal cAMP levels.[21] Because Epac needs micromolar concentration of cAMP to be activated,[4] theses findings suggest that this cAMP-GEF may be localized in subcellular membrane fractions of cardiomyocytes where intracellular cAMP concentration is high. Further experiments are required to determine the precise localization of Epac in cardiac myocytes and its association with proteins (ie, phosphodiesterases) that regulate cAMP gradient formation.

In our study, we showed that the Epac-specific cAMP analogue 8-CPT produces bursts of Ca^{2+} transients in neonatal cardiac myocytes. Our findings are in line with recent studies in pancreatic β-cells and INS-1 insulin-secreting cells, demonstrating a Epac-dependent mobilization of intracellular Ca^{2+} by the cAMP-elevating hormone glucagon-like peptide 1 and the implication of Epac in this effect.[25] In these cells, activation of endogenous Epac triggers Ca^{2+}-induced Ca^{2+} release[26] and it is suggested that a functional coupling exists between Epac and the RyR in these cellular systems.[27] Interestingly, the small GTPase Rap1 which is an effector of Epac is suspected to play a role in cAMP-induced $[Ca^{2+}]_i$ increase via SERCA3b in megakaryocytes.[28,29] Therefore,



Figure 6. Ad.VIVIT inhibits Epac-induced cardiomyocyte hypertrophy. A, Fluorescent microscopic analyses of the effects of Epac on sarcomeric organization. Morphology of representative myocytes 48 hours after infection with Ad.GFP (control), Ad.VIVIT, Ad.Epac^{WT}, or Ad.Epac^{WT} and Ad.VIVIT is shown. B, Photographic images of cardiac myocytes infected as above were digitized. Areas (10^{-6} m^2) of around 50 individualized cells per condition from 3 independent experiments were determined by computer-assisted planimetry. Values show the means±SEM. **P*<0.05, ***P*<0.01, and ****P*<0.001 compared with control or vs indicated values.

one could imagine in cardiac myocytes, that Epac might interact with Ca^{2+} release channels. Such hypothesis is currently undergoing investigation.

We found that Epac induced Rac activation in primary cardiomyocytes. This is in accordance with our recent findings showing that Epac induces Rac activation in a cAMP-dependent but PKA-independent manner in noncardiac cells such as primary cortical neurons and CHO cells.[11] Because we found that Rac was activated by Ca^{2+} on Epac stimulation, it is reasonable to think that Rac might be regulated by a GEF, which is sensitive to Ca^{2+}. Such a GEF has been reported for small GTPases of the Ras family.[30,31] Another molecular target which could be involved in Ca^{2+}-dependent Rac activation is the Rho GDP-dissociation inhibitor (RhoGDI). RhoGDI retains Rac into the cytoplasm and must dissociate to allow Rac to encounter its GEFs.[32,33] Recently, Price et al[34] have shown that Ca^{2+} induces a disruption of the Rac-RhoGDI complex leading to the translocation and activation of Rac in PC3 cells. Thus, one could speculate that such a mechanism might occur in cardiomyocytes and contribute to Epac-induced Ca^{2+}-dependent Rac activation

We report for the first time to our knowledge that Epac is implicated in the activation of NFAT in cardiac myocytes. The ability of Epac to stimulate NFAT activity was significantly inhibited by treatment with CsA and VIVIT, suggesting that calcineurin activity is regulated by Epac. Accordingly, we found that Epac upregulates the expression of MCIP1, a well known modulator of calcineurin signaling that possesses a series of NFAT binding sites in its gene promoter.[23,35] In addition, Ad.VIVIT partially reversed Epac-induced cardiomyocyte hypertrophy indicating that Epac is a new regulator of the hypertrophic calcineurin/NFAT signaling pathway. As the Ca^{2+}/calmodulin-dependent protein kinase II (CaMKII) is well-known to play a key role in cardiac hypertrophy,[36] it would be interesting to test the potential involvement of this signaling pathway in Epac-induced cardiac hypertrophy. In addition, Epac might be an important mediator of oxidative stress because an antioxidant blocked its effect on ANF-Luc. In accordance with this observation, Rac activation is thought to be an important mediator of ROS production induced by adrenoreceptor stimulation.[37] Furthermore, $G_{\alpha(12/13)}$-mediated ROS production is essential for angiotensin II-induced NFAT transcriptional activation.[24]

An important finding of the present study is that the effect of Epac on NFAT activation was inhibited by Rac^{S17N}, a negative dominant form of Rac. Inversely, Rac under its activated form increased NFAT activity and this effect was blocked by CsA. In line with these data, we found that Rac^{S17N} inhibited Epac-induced ANF transcriptional activity and cell growth. Altogether these results indicate that Rac is involved in the regulation of the hypertrophic calcineurin/NFAT signaling pathway initiated by Epac in cardiomyocytes. In contrast to our findings, a previous study has shown that Ras but not Rho GTPases regulates NFAT activity in cardiac cells.[38] The reasons for these discrepancies are still unclear. However, the stimulating effect of Rac on NFAT activity is supported by previous reports showing that humoral factors induce Rac-dependent NFAT activation in various cellular systems including immune and cardiac cells.[24,39,40] In addition, Rac^{G12V} has been shown to upregulate ANF expression in rat primary cardiac myocytes.[14]

Besides Epac, sustained activation of other cAMP effectors have been shown to be deleterious for cardiac cells. For instance, constitutive activation of PKA in the hearts of transgenic mice leads to cardiomyocyte hypertrophy and a progressive decline in cardiac function.[41] In a similar manner, increasing β_1-adrenergic receptor (β_1-AR) signaling cascade or $G_{\alpha s}$ protein levels induces, through intracellular Ca^{2+} elevation, a progressive development of cardiac hypertrophy and heart failure.[42,43] But although our data and the these observations point to a negative role of persistent activity of



Figure 7. Involvement of Rac in Epac-induced NFAT-dependent cardiomyocyte hypertrophy. A to C, Cardiomyocytes infected with Ad.GFP (control), Ad.Rac^{S17N}, Ad.Epac^{WT}, or Ad.Epac^{WT}, and Ad.Rac^{S17N} were transfected with either NFAT-Luc or ANF-Luc. Two days after, Luc activity was determined. Values are means±SEM of at least 3 separate experiments performed in triplicate. D and E, Ad.Rac^{S17N} reverses Epac-induced cardiomyocyte hypertrophy. D, Photographic images of cells infected for 2 days with Ad.GFP (control), Ad.Epac^{WT}, Ad.Rac^{S17N}, or Ad.Epac^{WT}, and Ad.Rac^{S17N} were digitized. E, The areas (10^{-6} m^2) of 50 individualized cells per condition from 3 independent experiments were determined by computer-assisted planimetry. Values show the means±SEM. *P<0.05, **P<0.01, and ***P<0.001 vs control cells or indicated values.

cAMP/Epac/PKA, any elevation of cAMP does not automatically cause deleterious effects. For instance, transgenic mice overexpressing β_2-AR in the heart,[44] Adenyl cyclase type 6 (AC6)[45] or AC8[46] do not show early signs of hypertrophy or heart failure. Clearly, these data show that the same second messenger conveys different information and cAMP compartmentation is a key actor and determines the quality of the response. As a next step, it therefore will be crucial to determine not only the spatial localization of Epac and its possible interaction with cAMP-PDE but also the neurohormonal factors which are involved in the regulation of its activity.

Thus, we propose a new cAMP signaling pathway in which activation of Epac leads to an increase in $[Ca^{2+}]_i$, which then activates calcineurin and Rac. The latter controls NFAT activation. This signaling cascade activates hypertrophic gene expression and induces the morphological aspects of cardiac myocyte hypertrophy. Our results thus open new insights into the signaling pathways by which cAMP may mediate its biological effects in cardiomyocytes.

Acknowledgments

This work was supported by grants from Inserm "Programme National de Recherche sur les Maladies Cardiovasculaires," the Association Française contre les Myopathies (AFM) and the Fondation de France. Andrea Marcantoni, Rikke Birkedal, and Eric Morel were recipients of grants from the Società Italiana di Farmacologia, AFM and Fondation Lefoulon-Delalande, respectively. We thank the Production and Control Department of Genethon, which is supported by the Association Française contre les Myopathies (AFM) in the frame of the GVPN network (http://www.gvpn.org) for providing us with Ad.GFP, Ad.Epac^{WT}, and Ad.Epac-ΔcAMP. We thank the vector core of the University Hospital of Nantes supported by AFM for the amplication of Ad.Rac^{S17N} and Ad.Rac^{G12V}. We are grateful to Valérie Nicolas, Catherine Rucker-Martin, and Claudine Delomenie for confocal analysis and quantitative PCR. We thank Rodolphe Fischmeister, Renée Ventura-Clapier and José Zugaza for critical readings of the manuscript.

References

1. Fimia GM, Sassone-Corsi P. Cyclic AMP signaling. *J Cell Sci*. 2001; 114:1971–1972.
2. de Rooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofers A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature*. 1998;396:474–477.
3. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybel AM. A family of cAMP-binding that directly activate Rap1. *Science*. 1998;282:2275–2279.
4. Bos JL. Epac : a new cAMP target and new avenues in cAMP research. *Nat Rev Mol Cell Biol*. 2003;2:369–377.
5. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. *J Biol Chem*. 2000;275:20829–20836.
6. Rehmann H, Schwede F, Doskeland SO, Wittinghofer A, Bos JL. Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac. *J Biol Chem*. 2003;278:38548–38556.
7. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. *J Cell Biol*. 2003;160:487–493.
8. Enserink JM, Price LS, Methi T, Mahic M, Sonnenberg A, Bos JL, Tasken K. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. *J Biol Chem*. 2004;279:44889–44896.
9. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK, Martinez A, Maenhaut C, Bos JL, Genieser HG, Doskeland SO. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. *J Biol Chem*. 2003;278:35394–35402.
10. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. *Nat Cell Biol*. 2000;2: 805–811.
11. Maillet M, Robert SJ, Cacquevel M, Gastineau M, Vivien D, Bertoglio J, Zugaza JL, Fishmeister R, Lezoualc'h F. Crosstalk between Rap1 and Rac regulates secretion of sAPP. *Nature Cell Biol*. 2003;5:633–639.
12. Hall A. Rho GTPases and the actin cytoskeleton. *Science*. 1998;279: 509–514.
13. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. *Circ Res*. 2000;86:1019–1023.
14. Clerk A, Pham FH, Fuller SJ, Sahai E, Aktories K, Marais R, Marshall C, Sugden PH. Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. *Mol Cell Biol*. 2001;21: 1173–1184.
15. Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, Rovira R, Blazina DR, Lee L, Bruder JT, Kovesdi I, Goldshmidt-Clermont PJ, Irani K, Finkel TA. requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. *J Clin Invest*. 1998; 102:929–937.
16. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, Schaefer E, Yager K. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active Rac1. *J Clin Invest*. 2000;105:875–886.
17. Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, Genieser HG, Doskeland SO, Blank JL, Bos JL. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. *Nat Cell Biol*. 2002;4:901–906.
18. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. *FASEB J*. 1991;5:3037–3046.
19. Balke CW, Shorofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. *Cardiovasc Res*. 1998;37:290–299.
20. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. *Cardiovasc Res*. 2004; 63:467–475.
21. Qiao J, Mei FC, Popov VL, Vergara LA, Cheng X. Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP. *J Biol Chem*. 2002;277:26581–26586.
22. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. *Science*. 1999;285:2129–2133.
23. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent Signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. *Circ Res*. 2000;87:61–68.
24. Fujii T, Onohara N, Maruyama Y, Tanabe S, Kobayashi H, Fukutomi M, Nagamatsu Y, Nishihara N, Inoue R, Sumimoto H, Shibasaki F, Nagao T, Nishida M, Kurose H. Gα12/13-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts. *J Biol Chem*. 2005;280:23041–23047.
25. Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, Rutter GA. Glucagon-like peptide-1 mobilizes intracellular Ca^{2+} and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. *Biochem J*. 2003;369:287–299.
26. Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, Bos JL, Schwede F, Genieser HG, Holz GG. Epac-selective cAMP Analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca^{2+}-induced Ca^{2+} release and exocytosis in pancreatic beta cells. *J Biol Chem*. 2003;278: 8279–8285.
27. Holz GG Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. *Diabetes*. 2004;53:5–13.
28. Magnier C, Bredoux R, Kovacs T, Quarck R, Papp B, Corvazier E, de Gunzburg J, Enouf J. Correlated expression of the 97 kDa sarcoendoplasmic reticulum Ca^{2+}-ATPase and Rap1B in platelets and various cell lines. *Biochem J*. 1994;297:343–350.
29. den Dekker E, Heemskerk JW, Gorter G, van der Vuurst H, Donath J, Kroner C, Mikoshiba K, Akkerman JW. Cyclic AMP raises intracellular Ca^{2+} in human megakaryocytes independent of protein kinase A. *Arterioscler Thromb Vasc Bio*. 2002;22:179–186.
30. Keiper M, Stope MB, Szatkowski D, Bohm A, Tysack K, Vom Dorp F, Saur O, Oude Weernink PA, Evellin S, Jakobs KH, Schmidt M. Epac- and Ca^{2+} -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. *J Biol Chem*. 2004;279: 46497–46508.
31. Quilliam LA, Rebhun JF, Castro AF. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. *Prog Nucleic Acid Res Mol Biol*. 2002;71:391–444.
32. Schmidt A, Hall A Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. *Genes Dev*. 2002;16:1587–1609.
33. Robbe K, Otto-Bruc A, Chardin P, Antonny B. Dissociation of GDP dissociation inhibitor and membrane translocation are required for efficient activation of Rac by the Dbl homology-pleckstrin homology region of Tiam. *J Biol Chem*. 2003;278:4756–4762.
34. Price LS, Langeslag M, Klooster JPT, Hordijk PL, Jalink K, Collard JG. Calcium signaling regulates translocation and activation of Rac. *J Biol Chem*. 2003;278:39413–39421.
35. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. *J Biol Chem*. 2002;277:30401–30407.
36. McKinsey TA, Olson EN. Cardiac histone acetylation-therapeutic opportunities abound. *Trends Genet*. 2004;20:206–213.
37. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, Nagai Y, Fujisawa Y, Miyatake A, Abe Y. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. *Cardiovasc Res*. 2005;65:230–238.
38. Ichida M, Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. *J Biol Chem*. 2001;276:3524–3530.

Circulation Research
FIRST PROOF ONLY

39. Turner H, Gomez M, MacKenzie E, Kirchem A, Lennard A, Cantrell D. Rac-1 regulates nuclear factor of activated T cells (NFAT) C1 nuclear translocation in response to Fcϵ receptor type 1 stimulation of mast cells. *J Exp Med*. 1998;188:527–537.
40. Vigorito E, Billadeu DD, Savoy D, McAdam S, Doody G, Fort P, Turner M. RhoG regulates gene expression and the actin cytoskeleton in lymphocytes. *Oncogene*. 2003;22:330–342.
41. Antos C, Frey N, Marx S, Reiken S, Gaburjakova M, Richardson J, Marks A, Olson E. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. *Circ Res*. 2001;89:997–1004.
42. Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej RK, Wagner TE, Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, and Vatner SF. (1997) Cardiomyopathy induced by cardiac Gsα overexpression. *Am J Physiol*. 1997;41:H585–H589.
43. Engelhardt S, Hein L, Wiesmann F, Lhose MJ. Progressive hypertrophy and heart failure in β1 adrenergic receptor transgenic mice. *Proc Natl Acad Sci U S A*. 1999;96:7059–7064.
44. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. *Science*. 1994;264:582–586.
45. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, Zhou JY, Zhu J, Entrikin D, Hammond HK. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. *Circulation*. 1999;99:3099–3102.
46. Lipskaia L, Defer N, Esposito G, Hajar I, Garel MC, Rockman HA, Hanoune J. Enhanced cardiac function in transgenic mice expressing a Ca(2+)-stimulated adenylyl cyclase. *Circ Res*. 2000;86:795–801.

Circulation
Research
JOURNAL OF THE AMERICAN HEART ASSOCIATION
FIRST PROOF ONLY